The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Experience with sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC) with visceral spread from PROCEED.
 
Nicholas J. Vogelzang
Employment - US Oncology
Stock and Other Ownership Interests - Caris Life Sciences
Honoraria - Pfizer; UpToDate
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Caris Life Sciences; Fujifilm; Genentech/Roche; HERON; Pfizer; Tolero Pharmaceuticals
Speakers' Bureau - AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Sanofi
Research Funding - Endocyte (Inst); Merck (Inst); Suzhou Kintor Pharmaceuticals (Inst); US Oncology (Inst); Viamet Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bayer/Onyx; Exelixis; Genentech/Roche; Pfizer; US Oncology
 
Philip W. Kantoff
Stock and Other Ownership Interests - Context Therapeutics; Druggablity Technologies; Placon; Seer; Tarveda Therapeutics
Consulting or Advisory Role - Bavarian Nordic; BIND Biosciences; Context Therapeutics; Druggablity Technologies; GE Healthcare; Genentech/Roche; Janssen; Merck; Metamark Genetics; New England Research Institutes; OncoCellMDX; Progenity; Sanofi; Seer; Tarveda Therapeutics; Thermo Fisher Scientific
Patents, Royalties, Other Intellectual Property - Chromosome Copy Number Gain as a Biomarker of Urothelial Carcinoma Lethality; Composition and Methods for Screening and Diagnosis of Prostate Cancer; Drug Combinations to Treat Cancer; Method for Predicting the Risk of Prostate Cancer Morbidity and Mortality; Methods and Kits for Determining Sensitivity to Cancer Treatment; Methods for Predicting Likelihood of Responding to Treatment; Predicting and Treating Prostate Cancer; Somatic ERCC2 Mutations Correlate with Cisplatin sensitivity in muscle-invasive Urothelial Carcinoma (Patent); Up-to-Date Royalties; Wolters Kluwer Royalties
Travel, Accommodations, Expenses - Druggablity Technologies; Sanofi
 
Mark C. Scholz
No Relationships to Disclose
 
Jeffrey L. Vacirca
Employment - New York Cancer and Blood Specialists
Leadership - Odonate Therapeutics
Stock and Other Ownership Interests - Odonate Therapeutics
 
Shaker R. Dakhil
No Relationships to Disclose
 
Sanjay Goel
Research Funding - Oncolytics (Inst)
Patents, Royalties, Other Intellectual Property - I have a patent with a co-inventor, John Mariadason, Ph.D, entitled "Method Of Determining The Sensitivity Of Cancer Cells To EGFR Inhibitors Including Cetuximab, Panitumumab And Erlotinib.", Patent No. 20090258364
 
Matthew Harmon
Employment - Dendreon
 
Hong Tang
Employment - Astellas Pharma; Dendreon; Juno Therapeutics
Stock and Other Ownership Interests - Astellas Pharma; Bauerfeind; Bristol-Myers Squibb; CVS; Dendreon; Juno Therapeutics; Marathon Pharma; Nektar; Sangamo Bioscience; Tesaro; Verastem
 
Bruce Brown
Employment - Astellas Scientific and Medical Affairs Inc; Dendreon
 
Andrew J. Armstrong
Honoraria - Dendreon; Janssen Oncology; Sanofi
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; Bayer; Dendreon; Janssen Biotech; Medivation; Novartis; Pfizer; Sanofi
Speakers' Bureau - Bayer; Dendreon; Sanofi
Research Funding - Active Biotech (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture technology (Inst)
Travel, Accommodations, Expenses - Astellas Scientific and Medical Affairs Inc; Bayer; Dendreon; Janssen Biotech